Drug Approval | March 28, 2024
Biocon to obtain approval for diabetes drug, Liraglutide in UK
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
Express Scripts to add Zepbound to National Preferred Formulary
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
The product will be manufactured at Lupin’s Nagpur facility in India
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion
In March 2023, Japan’s Ministry of Health and Labor Welfare approved Novo Nordisk’s once-weekly subcutaneous glucagon-like peptide-1
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
Subscribe To Our Newsletter & Stay Updated
